Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 17;19(16):2063–2073. doi: 10.1080/15384101.2020.1792686

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Informa UK Limited, trading as Taylor & Francis Group

PMC Copyright notice

Figure 3. — Cell apoptosis in MM cells treated by GANT61 with different treatment times. Cell apoptosis rate after treated by 10 μmol/L GANT61 with different treatment times (0, 18, 24, 36 h) in RPMI-8226 cells (a, b). Expressions of C-Caspase 3, Bcl-2, Bax and Survivin after treated by 10 μmol/L GANT61 with different treatment times (0, 18, 24, 36 h) in RPMI-8226 cells (c, d). Cell apoptosis rate after treated by 10 μmol/L GANT61 with different treatment times (0, 18, 24, 36 h) in U266 cells (e, f). Expressions of C-Caspase 3, Bcl-2, Bax and Survivin after treated by 10 μmol/L GANT61 with different treatment times (0, 18, 24, 36 h) in U266 cells (g, h). Comparison between two groups was determined by t-test. P value < 0.05 was considered significant. *P < 0.05; ***P < 0.001. MM, multiple myeloma; C-Caspase 3, Cleaved Caspase 3; Bcl-2, B-cell lymphoma-2.